Company profile
Ajax Therapeutics
Biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs
- Industry
- Biotechnology Research
- Employees
- 11
Ajax Therapeutics company summary
Ajax Therapeutics is a company in the Biotechnology Research industry. On LinkedIn the company has around 11 employees.
What technology does Ajax Therapeutics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Ajax Therapeutics
Ajax is pursuing uniquely selective approaches to develop novel next generation therapies for hematologic cancers, including myeloproliferative neoplasms (MPNs). By combining the deep cancer and structural biology insights of our founding scientists with the industry’s most advanced computational drug discovery and protein structure platforms, we aim to discover and develop more precisely designed therapies to address the significant unmet needs for patients with MPNs, including myelofibrosis, which are driven by aberrant JAK/STAT signaling due to mutations in JAK2, MPL and CALR genes. Our focus is developing next-generation JAK2 inhibitors that address the significant unmet needs of patients with myelofibrosis (MF) including the treatment of patients who are resistant or refractory to existing JAK2 therapies and providing disease modifying effects. Ajax’s lead clinical candidate, AJ1-11095, is the first Type II JAK2 inhibitor to enter the clinic. Type II JAK2 inhibitors have been shown to improve therapeutic efficacy, overcome disease persistence to Type I JAK2 inhibitors, including ruxolitinib, and, most importantly, reduce mutant JAK2 allele burden that drives MPNs. AJ1-11095 is currently in a Phase I study in the US for patients who have been failed by a Type I JAK2 inhibitor.
Compare companies similar to Ajax Therapeutics
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Ajax Therapeutics ajaxtherapeutics.com | Biotechnology Research | 11 | - | - |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Ajax Therapeutics
What does Ajax Therapeutics do?
Ajax is pursuing uniquely selective approaches to develop novel next generation therapies for hematologic cancers, including myeloproliferative neoplasms (MPNs). By combining the deep cancer and structural biology insights of our founding scientists with the industry’s most advanced computational drug discovery and protein structure platforms, we aim to discover and develop more precisely designed therapies to address the significant unmet needs for patients with MPNs, including myelofibrosis, which are driven by aberrant JAK/STAT signaling due to mutations in JAK2, MPL and CALR genes. Our focus is developing next-generation JAK2 inhibitors that address the significant unmet needs of patients with myelofibrosis (MF) including the treatment of patients who are resistant or refractory to existing JAK2 therapies and providing disease modifying effects. Ajax’s lead clinical candidate, AJ1-11095, is the first Type II JAK2 inhibitor to enter the clinic. Type II JAK2 inhibitors have been shown to improve therapeutic efficacy, overcome disease persistence to Type I JAK2 inhibitors, including ruxolitinib, and, most importantly, reduce mutant JAK2 allele burden that drives MPNs. AJ1-11095 is currently in a Phase I study in the US for patients who have been failed by a Type I JAK2 inhibitor.
How many employees does Ajax Therapeutics have?
Ajax Therapeutics has around 11 employees on LinkedIn.
Build a lead list from companies like Ajax Therapeutics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.